NanoBioMagnetics, Inc.

C.E. Seeney
NanoBioMagnetics, Inc., US

Keywords: Biotechnology and Medicine

Abstract:
NanoBioMagnetics, Inc. (NBMI is engaged in the development and commercialization of magnetic nanoparticle (MNP) technologies for human health applications in an emerging area of nanobiomedicine referred to as Organ-Assisting-Devices (OAD's). Fields of application for platform OAD technologies include vectored drug delivery and biostable implants. The Company?s initial commercialization focus is on biostable implants, in which MNP are used as components of implantable hearing devices (IHD) to amplify sound in middle ear tissues. NBMI also has active or developing programs in vectored (site-specific) drug delivery for the treatment of inner ear disorders, atrial fibrillation, and chemotherapeutics. The concept of using nanoparticles to drive middle ear tissues was successfully demonstrated with support from a Phase I SBIR award from the National Institutes of Health ( NIH NIDCD). Additional SBIR filings are proceeding. NBMI is developing proprietary OAD technologies based on the Company?s platform nanofabrication process, and applying designed MNP configuration for use as biostable implants and drug delivery vehicles (Patents pending). Upon validation of OAD technologies in specific applications, NBMI will seek commercialization partnerships with major pharmaceutical corporations for incorporation and commercialization of new product technologies. Financing is being sought to support business operations until revenue streams are in place.

Nanotech 2004 Conference Technical Program Abstract